TSHA

+ Watchlist + Portfolio

Taysha Gene Therapies, Inc.

Regulated industry Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.63
52-Week Range: $3.69 – $7.30
Market Cap: $1.46B
P/E (TTM): —
EPS (TTM): -0.41
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 3.77
PEG Ratio: —
Return on Equity: -47.05%
Return on Assets: -23.82%
Gross Margin: 100.00%
Operating Margin: -2792.32%
Profit Margin: 0.00%
Current Ratio: 17.77
Debt/Equity: 0.15
Total Debt: $56.71M
Free Cash Flow: $-80.97M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.06B

TSHA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.50M	$15.45M	$8.33M	$9.77M
Research & Development	$91.17M	$56.78M	$66.00M	$86.40M
Selling, General & Admin	$37.36M	$30.05M	$28.95M	$33.87M
Operating Expenses	$128.53M	$86.83M	$94.95M	$120.27M
Operating Income	-$126.03M	-$71.37M	-$86.62M	-$110.50M
EBITDA	-$161.04M	-$105.20M	-$87.95M	-$107.79M
Pretax Income	-$166.01M	-$111.57M	-$89.30M	-$109.00M
Net Income	-$166.01M	-$111.57M	-$89.30M	-$109.00M
Diluted EPS	-3.78	-0.96	-0.36	-0.34
Diluted Shares	43.95M	116.12M	250.13M	319.71M

TSHA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$87.88M	$143.94M	$139.04M	$319.77M
Current Assets	$96.42M	$149.87M	$142.13M	$324.65M
Total Assets	$126.28M	$172.73M	$160.36M	$343.32M
Current Liabilities	$62.79M	$36.76M	$26.23M	$26.55M
Long-Term Debt	$37.97M	$40.51M	$43.94M	$50.11M
Total Debt	$59.93M	$61.11M	$63.18M	$70.14M
Total Liabilities	$125.33M	$97.79M	$88.84M	$96.38M
Retained Earnings	-$401.44M	-$513.01M	-$602.30M	-$711.30M
Shareholders' Equity	$949.00K	$74.94M	$71.53M	$246.94M
Working Capital	$33.63M	$113.11M	$115.90M	$298.10M

TSHA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$88.39M	-$73.02M	-$81.22M	-$93.09M
Capital Expenditure	-$24.87M	-$7.37M	-$374.00K	-$738.00K
Free Cash Flow	-$113.26M	-$80.39M	-$81.60M	-$93.83M
Depreciation & Amortisation	$1.17M	$1.37M	$1.25M	$1.15M
Stock-Based Compensation	$18.04M	$7.91M	$13.10M	$13.30M
Investing Cash Flow	-$24.93M	-$7.35M	-$363.00K	-$604.00K
Financing Cash Flow	$52.10M	$136.39M	$76.68M	$274.59M
Net Change in Cash	-$61.22M	$56.02M	-$4.90M	$180.90M

TSHA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$2.30M	$1.99M	$0.00	$5.49M	$0.00	$0.00
Research & Development	$15.56M	$20.14M	$25.75M	$24.95M	$33.81M	$38.64M
Selling, General & Admin	$8.16M	$8.60M	$8.28M	$8.83M	$9.68M	$12.15M
Operating Expenses	$23.72M	$28.74M	$34.02M	$33.78M	$43.49M	$50.78M
Operating Income	-$21.42M	-$26.75M	-$34.02M	-$28.30M	-$43.49M	-$50.78M
EBITDA	-$21.23M	-$26.59M	-$32.43M	-$27.54M	-$42.11M	-$46.34M
Pretax Income	-$21.53M	-$26.88M	-$32.73M	-$27.85M	-$42.41M	-$46.64M
Net Income	-$21.53M	-$26.88M	-$32.73M	-$27.85M	-$42.41M	-$46.64M
Diluted EPS	-0.08	-0.09	-0.09	—	-0.12	-0.13
Diluted Shares	269.31M	297.99M	353.31M	—	366.63M	369.04M

TSHA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$116.59M	$312.76M	$297.34M	$319.77M	$276.58M	$455.41M
Current Assets	$120.71M	$316.26M	$299.95M	$324.65M	$282.25M	$461.43M
Total Assets	$138.36M	$333.33M	$316.55M	$343.32M	$300.35M	$470.43M
Current Liabilities	$22.56M	$25.35M	$28.63M	$26.55M	$20.10M	$25.98M
Long-Term Debt	$42.45M	$41.05M	$50.85M	$50.11M	$48.96M	$49.26M
Total Debt	$61.35M	$59.60M	$69.03M	$70.14M	$68.55M	$56.71M
Total Liabilities	$83.30M	$84.60M	$97.56M	$96.38M	$88.41M	$83.17M
Retained Earnings	-$623.83M	-$650.72M	-$683.45M	-$711.30M	-$753.71M	-$800.35M
Shareholders' Equity	$55.06M	$248.73M	$218.99M	$246.94M	$211.94M	$387.27M
Working Capital	$98.15M	$290.92M	$271.32M	$298.10M	$262.15M	$435.46M

TSHA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$22.02M	-$20.18M	-$24.17M	-$26.72M	-$40.88M	-$40.42M
Capital Expenditure	-$378.00K	-$2.00K	-$108.00K	-$250.00K	-$3.02M	—
Free Cash Flow	-$22.40M	-$20.18M	-$24.27M	-$26.97M	-$43.90M	-$40.42M
Depreciation & Amortisation	$283.00K	$277.00K	$286.00K	$299.00K	$295.00K	$291.00K
Stock-Based Compensation	$3.29M	$3.19M	$3.29M	$3.53M	$5.55M	$5.81M
Investing Cash Flow	-$371.00K	$62.00K	-$48.00K	-$247.00K	-$3.02M	$1.00K
Financing Cash Flow	-$52.00K	$216.29M	$8.80M	$49.56M	$711.00K	$216.66M
Net Change in Cash	-$22.44M	$196.17M	-$15.42M	$22.59M	-$43.19M	$176.23M

Market Snapshot

About

Taysha Gene Therapies is a clinical-stage gene therapy company focused on developing treatments for monogenic diseases of the central nervous system. The company utilizes adeno-associated virus-based gene therapies designed to deliver functional genes to address genetic mutations. Taysha is advancing a pipeline of investigational therapies for rare neurological disorders.